Broggini M, Buraggi G, Brenna A, Riva L, Codegoni A M, Torri V, Lissoni A A, Mangioni C, D'Incalci M
Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea, 62,20157 Milan, Italy.
Anticancer Res. 2000 Nov-Dec;20(6C):4835-40.
Alterations in cell cycle regulating proteins are common in many cancer types. Recent data suggest a possible link between CDC25 phosphatases overexpression and malignancy. Our objective was to evaluate the expression of the three cell cycle-related phosphatases CDC25A, CDC25B and CDC25C in patients with ovarian cancer. All the patients had a minimal follow up of three years. CDC25A, CDC25B and CDC25C expression were investigated by immunohistochemistry in 106 patients with ovarian cancer. CDC25A and CDC25B were found expressed in almost all the samples analyzed, while CDC25C was undetectable in more than 80% of the patients. The low evaluable data on CDC25C expression, did not allow any association between the expression of this phosphatase and prognosis. The expression of CDC25A and CDC25B showed some evidences of association with a poor prognosis (p = 0.034 and p = 0.058 respectively). This relationship was independent of other factors such as tumor grade, histotype, stage and residual tumor after surgery. In the same patients the examined parameters (residual tumor, grade, stage and histotype) did show the expected relation with survival. The results indicate that high CDC25A and CDC25B expression is related to a worse prognosis in ovarian cancer patients. CDC25 phosphatases expression can be regarded as a possible prognostic factor for ovarian cancer and these proteins should be evaluated as potential molecular targets of novel drugs against this human neoplasm.
细胞周期调节蛋白的改变在许多癌症类型中都很常见。最近的数据表明，细胞周期蛋白磷酸酶25（CDC25）过表达与恶性肿瘤之间可能存在联系。我们的目的是评估三种细胞周期相关磷酸酶CDC25A、CDC25B和CDC25C在卵巢癌患者中的表达情况。所有患者的最短随访时间为三年。通过免疫组织化学方法对106例卵巢癌患者的CDC25A、CDC25B和CDC25C表达进行了研究。发现CDC25A和CDC25B在几乎所有分析的样本中均有表达，而超过80%的患者未检测到CDC25C。关于CDC25C表达的可评估数据较少，无法确定该磷酸酶的表达与预后之间的任何关联。CDC25A和CDC25B的表达显示出与预后不良相关的一些证据（分别为p = 0.034和p = 0.058）。这种关系独立于其他因素，如肿瘤分级、组织类型、分期和术后残留肿瘤。在同一组患者中，所检查的参数（残留肿瘤、分级、分期和组织类型）确实与生存呈现出预期的关系。结果表明，CDC25A和CDC25B的高表达与卵巢癌患者的预后较差有关。CDC25磷酸酶的表达可被视为卵巢癌可能的预后因素，这些蛋白应作为针对这种人类肿瘤的新型药物的潜在分子靶点进行评估。
